Drug Trial Radar · NCT07316361
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Dec 2, 2029
Study completion Dec 2, 2031
Sponsor
- Lead sponsor
- Biogenea Pharmaceuticals Ltd.Biogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jan 5, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma. All participants receive GYNORYLAQ-TM, a personalized neoantigenic peptide vaccine generated by the GYNORYLAQ-EC™ quantum-classical engine, in combination with systemic and supportive drug regimens that are individually selected and prescribed by the treating medical oncologist, Dr Emmanouelides Christos, according to contemporary standards of care and the clinical status of each patient. Only the GYNORYLAQ-TM vaccine is considered investigational within this protocol; all concomitant drugs (including antineoplastic agents and supportive care medications) are non-investigational, chosen and adjusted at the discretion of Dr Emmanouelides Christos. The primary objectives are to evaluate the safety/tolerability of GYNORYLAQ-TM in this real-world therapeutic context and the feasibility of quantum-guided, GMP-grade personalized vaccine manufacture. Secondary and exploratory objectives characterize vaccine-induced T-cell immunity and explore correlations between quantum/physics-based scores and clinical/immunologic outcomes.
Conditions
- Endometrial Carcinoma
- Endometrial Carcinoma Stage III
Interventions
• Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide VaccineBiological
GYNORYLAQ-TM is an individualized, peptide-based cancer vaccine composed of synthetic neoantigenic peptides uniquely selected for each patient using the GYNORYLAQ-EC™ quantum-classical computational engine. Tumour and matched normal samples are sequenced to identify somatic variants (missense mutations, indels, frameshifts). For each patient, candidate peptide-HLA pairs are generated and scored using an integrated feature set that includes sequence-based presentation predictions, antigen-processing priors, quantum-geometric similarity measures, structural pocket occupancy, and docking-derived thermodynamic parameters (ΔG°, K\_d). Peptides passing predefined gates on binding strength, quantum similarity, and predicted immunogenicity are prioritized to form a personalized panel (typically \~10-20 peptides, including 8-11mer class I and longer helper/cross-presenting peptides) suitable for GMP synthesis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent AEs/SAEs and DLTs (CTCAE v5.0) With GYNORYLAQ™ Plus Oncologist-Selected Drug RegimensTime frame: From first vaccination through 30 days after last vaccination.
- Feasibility of Quantum-Guided Vaccine ManufacturingTime frame: Up to 16 weeks from tumor tissue acquisition to vaccine release and first vaccination.
- Vaccine Immunogenicity (Early Phase I Co-Primary)Time frame: Baseline to ~Week 24 and at end of treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Biogenea Pharmaceuticals Ltd & Interbalkan Medical Center - International Oncology Center
Thessaloniki, Thessaloniki, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.